Utilization Review Policy 163

POLICY: Oncology – Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk for subcutaneous use – Genentech Inc.)

EFFECTIVE DATE: 7/1/2021
LAST REVISED DATE: 03/22/2023

COVERAGE CRITERIA FOR: All UCare Plans

OVERVIEW

Herceptin Hylecta is indicated for the following uses:[1]

- **Breast Cancer, adjuvant treatment** of adults with human epidermal growth factor receptor 2 (HER2) overexpressing node positive or node negative (estrogen receptor [ER]-/progesterone receptor [PR]-negative or with one high risk feature) breast cancer:
  - **a)** As part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel.
  - **b)** As part of a treatment regimen with docetaxel and carboplatin.
  - **c)** As a single agent following multi-modality anthracycline based therapy.
- **Breast Cancer**, metastatic, in adults with HER2-overexpressing disease:
  - **a)** In combination with paclitaxel for first-line treatment.
  - **b)** As a single agent for the treatment of patients who have received one or more chemotherapy regimens for metastatic disease.

Guidelines

The National Comprehensive Cancer Network (NCCN) breast cancer clinical practice guidelines (version 2.2023 – March 3, 2023) state that Herceptin Hylecta may be substituted for trastuzumab intravenous and used as a single-agent or in combination with other systemic therapies.[2,3] The guidelines note the different dose and dosage form of Herceptin Hylecta compared with trastuzumab. It is also noted that Herceptin Hylecta cannot be substituted for Kadcyla™ (ado-trastuzumab emtansine intravenous infusion) or Enhertu® (fam-trastuzumab deruxtecan-nxki intravenous infusion). Trastuzumab is recommended as part of a preferred regimen in the preoperative, adjuvant, and metastatic setting for HER2-positive disease.

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Herceptin Hylecta. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the criteria and dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Herceptin Hylecta, as well as the monitoring required for adverse events and long-term efficacy, approval requires Herceptin Hylecta to be prescribed by or in consultation with a physician who specializes in the condition being treated.

This document is confidential and proprietary to UCare. Unauthorized use and distribution are prohibited.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Herceptin Hylecta is recommended for request meeting both the biosimilar step therapy requirements and indication requirements.

Biosimilar Step Therapy Requirements (New Starts Only)

Criteria. *The patient must meet the following criteria (A, B, or C):*

A) For patients new to trastuzumab with hyaluronidase-oysk therapy only, must have a trial of Trazimera or Kanjinti prior to approval of Herceptin Hylecta. New starts to therapy defined as no use of trasztuzumab products within the past 180 days for Medicaid and Commercial patients. New starts to therapy defined as no use of trastuzumab products within the past 365 days for Medicare patients.

B) Patient cannot use trastuzumab intravenous products due to an inability to obtain or maintain intravenous access.

C) Patient has a contraindication or other clinical reason why a biosimilar cannot be tried before Herceptin Hylecta.

Note: Biosimilar step only required for indications FDA-Approved for both Herceptin Hylecta and the biosimilar(s).

FDA-Approved Indications

1. Breast Cancer. Approve for the duration noted below if the patient meets ALL of the criteria (A, B, C, and D):

A) Patient is ≥ 18 years of age; AND

B) Patient has human epidermal growth factor receptor 2 (HER2)-positive disease; AND

C) Patient meets one of the following criteria (i or ii):

i. Approve for up to 1 year (total) if the medication is used for adjuvant treatment; OR

ii. Approve for 1 year if the medication is used for recurrent or metastatic disease; AND

D) The medication is prescribed by or in consultation with an oncologist.

Dosing. Approve 600 mg/10,000 units (600 mg trastuzumab and 10,000 units hyaluronidase) Herceptin Hylecta administered subcutaneously once every three weeks.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Herceptin Hylecta has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Herceptin Hylecta™ for subcutaneous use [prescribing information]. South San Francisco, CA: Genentech, Inc.; February 2019.
2. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 1.2019 – March 14, 2019). © 2019 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on March 18, 2019.

This document is confidential and proprietary to UCare. Unauthorized use and distribution are prohibited.

3. The NCCN Drugs and Biologics Compendium. © 2019 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on March 18, 2019. Search term: trastuzumab hyaluronidase.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	**Breast Cancer:** Added age criterion for approval.	03/17/2021
Annual Revision	**Breast Cancer:** "Recurrent" was added to the criteria that the patient has metastatic disease	03/30/2022
Annual Revision	**No criteria changes**	03/22/2023

This document is confidential and proprietary to UCare. Unauthorized use and distribution are prohibited.